LymphoDrain SIGNED
LymphoDrain: The definitive solution for chronic lymphedema
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0LymphoDrain project word cloud
Explore the words cloud of the LymphoDrain project. It provides you a very rough idea of what is the project "LymphoDrain" about.
Project "LymphoDrain" data sheet
The following table provides information about the project.
| Coordinator |
LYMPHATICA MEDTECH SA
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Total cost | 2˙586˙750 € |
| EC max contribution | 1˙810˙725 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-09-01 to 2022-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | LYMPHATICA MEDTECH SA | CH (LAUSANNE) | coordinator | 1˙810˙725.00 |
Map
Project objective
Lymphedema (LE) is a chronic disfunction of the lymphatic system causing fluid accumulation in the limbs, which affects more than 100 million patients worldwide. Its occurrence is closely related to cancer, being a very common side effect of cancer therapies, but can also arise from genetic disorders or due to injury, trauma, venous disorders, obesity, immobility, etc. Despite recent advances, at present there is no cure for LE which becomes a chronic disorder. The disease must be treated constantly by the patient, to avoid complications, with daily use of compression garments, physiotherapy and skin care. Thus, it creates a constant disability for the patient and, more importantly, it affects his/her ability to work and to live a normal life. In Europe, the financial impact of LE is valued at around €832 million in health and social welfare bills, with an additional €2.3 billion used to treat infections secondary to LE, as well as an additional €4.4 billion in loss of earnings as a result of productive incapacity of the patients. In addition, the prevalence of chronic LE is expected to grow as the life expectancy increases and the global population ages. There is an urgent need for innovative approaches to restore continuous lymph flow drainage in affected tissues, producing a definitive solution for LE. Lymphatica´s subcutaneous implant, LymphoDrain, consists of a draining catheter and a micro-pump externally controlled by a wearable device, and replaces the function of lymphatic vessels. It is implanted via a minimally invasive procedure, and results in the resolution of the physiological impairments caused by LE reducing pain, the risk of potential complications and the need for additional treatments. Lymphatica´s goal is to convert LymphoDrain in the first definitive solution for LE patients and a clear solution for reducing the impact of LE on both the healthcare system and the economy of each country.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHODRAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LYMPHODRAIN" are provided by the European Opendata Portal: CORDIS opendata.